Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The combination of nab-paclitaxel and gemcitabine (nab-P/Gem) is widely used for treating metastatic pancreatic cancer (MPC). We aimed to evaluate the therapeutic outcomes and prognostic role of treatment-related peripheral neuropathy in patients with MPC treated with nab-P/Gem in clinical practice. Methods: MPC patients treated with nab-P/Gem as the first-line chemotherapy were included. All 88 Korean patients underwent at least two cycles of nab-P/Gem combination chemotherapy (125 and 1,000 mg/m2, respectively). Treatment-related adverse events were monitored through periodic follow-ups. Overall survival and progression-free survival were estimated by the Kaplan– Meier method, and the Cox proportional hazards regression linear model was applied to assess prognostic factors. To evaluate the prognostic value of treatment-related peripheral neuropathy, the landmark point analysis was used. Results: Patients underwent a mean of 6.7±4.2 cycles during 6.3±4.4 months. The median overall survival and progression-free survival rates were 14.2 months (95% confidence interval [CI], 11.8 to 20.3 months) and 8.4 months (95% CI, 7.1 to 13.2 months), respectively. The disease control rate was 84.1%; a partial response and stable disease were achieved in 30 (34.1%) and 44 (50.0%) patients, respectively. Treatment-related peripheral neuropathy developed in 52 patients (59.1%), and 13 (14.8%) and 16 (18.2%) patients experienced grades 2 and 3 neuropathy, respectively. In the landmark model, at 6 months, treatment-related peripheral neuropathy did not have a significant correlation with survival (p=0.089). Conclusions: Nab-P/Gem is a reasonable choice for treating MPC, as it shows a considerable disease control rate while the treatment-related peripheral neuropathy was tolerable. The prognostic role of treatment-related neuropathy was limited.
Abstract
Background/Aims: The combination of nab-paclitaxel and gemcitabine (nab-P/Gem) is widely used for treating metastatic pancreatic cancer (MPC). We aimed to evaluate the therapeutic outcomes and prognostic role of treatment-related peripheral neuropathy in patients with MPC treated with nab-P/Gem in clinical practice. Methods: MPC patients treated with nab-P/Gem as the first-line chemotherapy were included. All 88 Korean patients underwent at least two cycles of nab-P/Gem combination chemotherapy (125 and 1,000 mg/m2, respectively). Treatment-related adverse events were monitored through periodic follow-ups. Overall survival and progression-free survival were estimated by the Kaplan– Meier method, and the Cox proportional hazards regression linear model was applied to assess prognostic factors. To evaluate the prognostic value of treatment-related peripheral neuropathy, the landmark point analysis was used. Results: Patients underwent a mean of 6.7±4.2 cycles during 6.3±4.4 months. The median overall survival and progression-free survival rates were 14.2 months (95% confidence interval [CI], 11.8 to 20.3 months) and 8.4 months (95% CI, 7.1 to 13.2 months), respectively. The disease control rate was 84.1%; a partial response and stable disease were achieved in 30 (34.1%) and 44 (50.0%) patients, respectively. Treatment-related peripheral neuropathy developed in 52 patients (59.1%), and 13 (14.8%) and 16 (18.2%) patients experienced grades 2 and 3 neuropathy, respectively. In the landmark model, at 6 months, treatment-related peripheral neuropathy did not have a significant correlation with survival (p=0.089). Conclusions: Nab-P/Gem is a reasonable choice for treating MPC, as it shows a considerable disease control rate while the treatment-related peripheral neuropathy was tolerable. The prognostic role of treatment-related neuropathy was limited.
참고문헌 (30)
- Siegel RL, "Cancer statistics, 2016", CA Cancer J Clin, 66, pp.7~30 (2016)
- Rahib L, "Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States", Cancer Res, 74, pp.2913~2921 (2014)
- Manji GA, "Current and emerging therapies in metastatic pancreatic cancer", Clin Cancer Res, 23, pp.1670~1678 (2017)
- Abou-Khalil J, "Surgical strategies and novel therapies for locally advanced pancreatic cancer", J Surg Oncol, 116, pp.16~24 (2017)
- Vogel A, "Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT)", BMC Cancer, 16, pp.817~ (2016)
- Von Hoff DD, "Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine", N Engl J Med, 369, pp.1691~1703 (2013)
- Ottaiano A, "Nab-paclitaxel and gemcitabine in advanced pancreatic cancer: the one-year experience of the National Cancer Institute of Naples", Anticancer Res, 37, pp.1975~1978 (2017)
- Carrato A, "Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study", Expert Rev Pharmacoecon Outcomes Res, 15, pp.579~589 (2015)
- Bertocchi P, "Gemcitabine plus nabpaclitaxel as second-line and beyond treatment for metastatic pancreatic cancer: a single institution retrospective analysis", Rev Recent Clin Trials, 10, pp.142~145 (2015)
- Zhang Y, "Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity", Exp Hematol Oncol, 4, pp.29~ (2015)
- Cho IR, "Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer “in a Korean” population: a singlecenter cohort study", Semin Oncol, 44, pp.420~427 (2017)
- Lee JJ, "Peripheral neuropathy induced by microtubulestabilizing agents", J Clin Oncol, 24, pp.1633~1642 (2006)
- Dumontet C, "Microtubule-binding agents: a dynamic field of cancer therapeutics", Nat Rev Drug Discov, 9, pp.790~803 (2010)
- Goldstein D, "Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: a subset analysis from a randomised phase III trial (MPACT)", Eur J Cancer, 52, pp.85~91 (2016)
- Tabernero J, "Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nabpaclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer", Oncologist, 20, pp.143~150 (2015)
- Kunzmann V, "Tumor reduction in primary and metastatic pancreatic cancer lesions with nabpaclitaxel and gemcitabine: an exploratory analysis from a phase 3 study", Pancreas, 46, pp.203~208 (2017)
- Luo G, "Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy", Ann Surg Oncol, 22, pp.670~676 (2015)
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- Jones M, "Immortal time bias in observational studies of time-to-event outcomes", J Crit Care, 36, pp.195~199 (2016)
- Goldstein D, "nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial", J Natl Cancer Inst, 107, pp.dju413~ (2015)
- Lo Re G, "Prognostic factors of survival in patients treated with nabpaclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experience", Oncotarget, 6, pp.8255~8260 (2015)
- Ueno H, "Phase I", II study of nab-paclitaxel plus gemcitabine for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer, 2016, pp.77, 595~603
- Vogel A, "Patients with advanced pancreatic cancer and hyperbilirubinaemia: review and German expert opinion on treatment with nab-paclitaxel plus gemcitabine", Oncol Res Treat, 38, pp.596~603 (2015)
- Peng L, "Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis", Eur J Cancer Care (Engl), 26, pp.e12407~ (2017)
- Rivera E, "Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer", Cancer Chemother Pharmacol, 75, pp.659~670 (2015)
- Ahn DH, "A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis", Ther Adv Med Oncol, 9, pp.75~82 (2017)
- Scheithauer W, "Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial", J Gastrointest Oncol, 7, pp.469~478 (2016)
- Kusumanto YH, "Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor", Angiogenesis, 6, pp.283~287 (2003)
- Matsuo Y, "Cytokine network: new targeted therapy for pancreatic cancer", Curr Pharm Des, 18, pp.2416~2419 (2012)
- Yoshie O, "Chemokine receptors as therapeutic targets", Nihon Rinsho Meneki Gakkai Kaishi, 36, pp.189~196 (2013)